Rocket Pharma (RCKT) Stock Forecast & Price Target

Rocket Pharmaceuticals is attractive because its Danon disease program now has a clearer pivotal bar—7 of 12 patients must meet both co-primary criteria at 12 months—and the early evidence is encouraging, with all six evaluable Phase I patients meeting responder criteria and five of six remaining transplant-free at 58 months. The first three Cohort 4 patients showed no TMA or capillary leak after the dose was recalibrated to 3.8×10^13 GC/kg, while prior cohorts showed LVMI reductions of about 30% to 36% in three patients and durable biomarker improvement overall. Financially, the company ended 2Q26 with $283.7 million in cash and secured up to $150 million from Hercules Capital, extending runway into 3Q28 and supporting execution toward mid-2027 dosing completion and mid-2028 top-line data.

Rocket Pharmaceuticals is viewed negatively because it remains an early commercial-stage gene therapy company with one approved product that is not yet generating revenue, while most of the pipeline is still clinical stage and exposed to high clinical, regulatory, and manufacturing risk. Its continuing cash burn and need for additional debt or equity financing raise dilution and covenant concerns, especially if funding is unavailable on acceptable terms or if the FDA requires longer, more capital-intensive pivotal trials. The outlook is also constrained by limited visibility on patient eligibility and diagnosis rates, as well as uncertainty around RP-A501 after its clinical hold and the commercial practicality of pricing durable gene therapies.